BI Asset Management Fondsmaeglerselskab A S Has $7.63 Million Stock Holdings in Pfizer Inc. $PFE

BI Asset Management Fondsmaeglerselskab A S decreased its position in Pfizer Inc. (NYSE:PFE) by 63.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 299,606 shares of the biopharmaceutical company’s stock after selling 514,481 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Pfizer were worth $7,634,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the third quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beats — Pfizer reported 4Q revenue of $17.56B and adjusted EPS that beat consensus, reinforcing near‑term cash generation and supporting optimism about pipeline investments. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: GLP‑1 Phase 2b success — Lead obesity candidate MET‑097i (VESPER‑3) met its primary endpoint with up to 12.3% placebo‑adjusted weight loss and sustained effect after switching dosing cadence, giving Pfizer a credible entry into a fast‑growing GLP‑1 market. This is a near‑term clinical catalyst that drove recent upside. Pfizer Announces Positive Phase 2b Results for Obesity Drug
• Positive Sentiment: Oncology + AI growth story — Analysts and analysts’ commentary highlight Pfizer’s expanded oncology pipeline (post‑Seagen) and broad AI partnerships that management says will speed discovery and cut costs, offering multiple medium‑to‑long‑term revenue drivers beyond GLP‑1. Growth from Oncology and AI
• Neutral Sentiment: TrumpRx discounts — Pfizer launched a program on TrumpRx offering discounts on 30+ medicines to improve affordability; positive for access/reputation but could pressure list prices or commercial mix (impact on earnings unclear). Pfizer Launches Cost Savings Program on TrumpRx
• Neutral Sentiment: FY‑2026 guidance mixed — Pfizer gave EPS guidance of $2.80–3.00 (midpoint slightly below some consensus) and revenue guidance that straddles estimates; this tempering likely capped the rally as investors parsed sustainability. Guidance Update
• Negative Sentiment: Market reaction and analyst caution — Despite the beats and clinical news, some outlets reported a mixed investor response to the weight‑loss data and a few firms maintained Hold/neutral ratings or modest price targets, which contributed to the pullback in PFE today. Analysts See Cautious Upside
• Negative Sentiment: Program pauses — Updates that paused some modRNA shingles work with BioNTech introduce specific R&D uncertainty and are a reminder of binary clinical risks across the pipeline. Pfizer and BioNTech Pause modRNA Shingles Ambitions

Analysts Set New Price Targets

Several equities analysts have weighed in on PFE shares. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. HSBC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Trading Down 1.1%

PFE opened at $26.49 on Friday. The company’s 50 day moving average is $25.58 and its 200-day moving average is $25.08. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a market cap of $150.60 billion, a P/E ratio of 19.48 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the company earned $0.63 EPS. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s payout ratio is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.